BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $390.9231.

A number of brokerages have weighed in on ONC. Truist Financial upped their price target on BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Morgan Stanley reissued an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Citizens Jmp restated a “market outperform” rating and issued a $396.00 target price on shares of BeOne Medicines in a research note on Wednesday, July 1st. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th.

Insider Buying and Selling at BeOne Medicines

In other news, COO Xiaobin Wu sold 1,484 shares of BeOne Medicines stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the completion of the transaction, the chief operating officer owned 40 shares in the company, valued at approximately $10,774.80. The trade was a 97.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the transaction, the chief executive officer directly owned 8,122 shares in the company, valued at $2,484,925.90. The trade was a 94.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 233,647 shares of company stock worth $70,335,553 over the last ninety days. Corporate insiders own 6.19% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Capital International Investors raised its position in BeOne Medicines by 1.3% in the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after purchasing an additional 67,808 shares during the last quarter. Siren L.L.C. grew its holdings in shares of BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after purchasing an additional 7,010 shares during the last quarter. Morgan Stanley grew its holdings in shares of BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after purchasing an additional 84,367 shares during the last quarter. Bank of America Corp DE increased its stake in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares in the last quarter. Finally, Candriam S.C.A. increased its stake in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after buying an additional 62,470 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Trading Down 1.7%

ONC stock opened at $312.02 on Friday. BeOne Medicines has a 1-year low of $253.95 and a 1-year high of $385.22. The firm has a market cap of $34.23 billion, a P/E ratio of 69.80 and a beta of 0.49. The business’s 50 day moving average is $290.21 and its 200-day moving average is $308.95. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities analysts anticipate that BeOne Medicines will post 5.86 earnings per share for the current fiscal year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.